MedTrace Logo

The National Register of Antipsychotic Medication in Pregnancy (NRAMP)

NCT00686946 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-11-28

No results posted yet for this study

Summary

The National Register of Antipsychotic Medication in Pregnancy (NRAMP)is an observational, nationwide study involving women of child-bearing age who take antipsychotic medication during pregnancy. It follows the pathway of mother and baby during pregnancy and for the first 12 months of the baby's life, in order to develop evidence-based guidelines for the best use and effect of antipsychotic medication during pregnancy, thereby informing clinical treating teams with regard to the management of their patients in this vulnerable population group.

The investigators hypothesize that the provision of such evidence-based guidelines will improve the management and outcomes for mother and baby during pregnancy, birth and the postnatal phase, providing a positive impact on maternal and child health and wellbeing for present and future generations.

Conditions

  • Pregnancy
  • Mental Disorders

Sponsors & Collaborators

  • Janssen-Cilag Ltd.

    collaborator INDUSTRY

  • AstraZeneca

    collaborator INDUSTRY

  • Hospira, now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • The Alfred

    lead OTHER

Principal Investigators

  • Prof Jayashri Kulkarni, MBBS,FRANZCP · Monash Alfred Psychiatry Research Centre (MAPrc)

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00686946 on ClinicalTrials.gov